Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 12Withdrawn 3Unknown 2Terminated 2Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Neoplasms 57Breast Neoplasms 52Leukemia, Myeloid, Acute 40Carcinoma, Non-Small-Cell Lung 40Lymphoma 35Pancreatic Neoplasms 30Leukemia, Lymphocytic, Chronic, B-Cell 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 27Ovarian Neoplasms 25Multiple Myeloma 25Lymphoma, Non-Hodgkin 25Recurrence 24Lung Neoplasms 23Melanoma 22Lymphoma, Large B-Cell, Diffuse 21Prostatic Neoplasms 20Glioblastoma 20Brain Neoplasms 19Colorectal Neoplasms 18Lymphoma, Follicular 17Squamous Cell Carcinoma of Head and Neck 16Sarcoma 16Lymphoma, B-Cell 15Lymphoma, Mantle-Cell 14Myelodysplastic Syndromes 13Urinary Bladder Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Glioma 12

Interventions

X-Rays 1Vorinostat 1Sorafenib 1Magnetic Resonance Spectroscopy 1Erlotinib Hydrochloride 1Curcumin 1Cetuximab 1AH 111585 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Advanced Cancers × Clear all
NCT02193672 2014-07-18

A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

NCT01432119 2013-04-09

Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡